Stribild® (elvitegravir/cobicistat/emtricitabine/ tenofovir) – Expanded indication and updated warnings
January 27, 2017 – The FDA approved Gilead Sciences’ Stribild (elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate), as a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Stribild.
Top